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Abstract 
Introduction 
We studied if Bronchiectasis (BR) and Rheumatoid arthritis (RA) when manifesting as an 
overlap syndrome (BROS) was associated with worse outcomes than other BR aetiologies 
applying the Bronchiectasis Severity Index (BSI).  
Methods 
We interrogated the Bronchiectasis Severity Index (BSI) databases of 1716 patients across 6 
centres: Edinburgh, UK (608 patients), Dundee, UK (N=286), Leuven, Belgium (N=253), 
Monza, Italy (N=201), Galway Ireland (N=242) and Newcastle, UK (N=126). Patients were 
categorised as BROS (those with RA and Bronchiectasis without interstitial lung disease), 
idiopathic bronchiectasis, Bronchiectasis-COPD overlap syndrome (BCOS) and “other” BR 
aetiologies. Mortality rates, hospitalisation and exacerbation frequency were recorded. 
Results 
We identified 147 patients with BROS (8.5% of cohort). There was a statistically significant 
relationship between BROS and mortality although this was not associated with higher rates 
of bronchiectasis exacerbations or bronchiectasis-related hospitalisations. The mortality rate 
over a mean of 48 months was 9.3% for idiopathic BR, 8.6% in patients with “other” causes 
of BR, 18% for RA and 28.5% for BCOS. Mortality was statistically higher in BROS and 
BCOS compared with all other aetiologies. The BSI scores were statistically but not clinically 
significantly higher in those with BROS when compared to idiopathic BR (BSI mean 7.7 vs. 
7.1 respectively, p <0.05). BCOS had significantly higher BSI scores (mean 10.4), 
Pseudomonas aeruginosa colonization rates (24%) and prior hospitalisation rates (58%). 
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Conclusions 
 Both BROS and BCOS groups have an excess of mortality -the mechanisms for this may be 
complex but these data highlight that these subgroups require additional study to understand 
this excess mortality. 
 
=250words 
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Introduction 
 
Non-cystic fibrosis bronchiectasis (hereafter referred to as bronchiectasis-BR) is a chronic 
respiratory disorder characterised by recurrent cough, sputum production and respiratory 
infections[1] Pathologically, patients have abnormally dilated bronchi leading to impairment 
of host defence, chronic infection with bacteria and airways inflammation.[2,3] 
Rheumatoid arthritis (RA) is a common auto-immune disease associated with many extra-
articular features. RA has numerous pulmonary complications including interstitial lung 
diseases that may lead to “traction bronchiectasis” whilst the association between RA and 
bronchiectasis without interstitial lung disease (hereafter BROS) is well recognised. Recent 
studies note a significantly higher prevalence of symptomatic bronchiectasis in RA subjects 
(approximately 3%) as compared to 0.03% in the general population [4]. Supporting this are 
high resolution CT scanning (HRCT) studies consistently reporting high prevalence of up to 
30% of radiological evidence of BR in RA populations [5,6]. 
Historical single centre studies have suggested that patients with BROS may have a worse 
clinical course than those patients with bronchiectasis due to other aetiologies. Recently we 
have identified that when compared to patients with RA alone, BROS patients have a higher 
indices of RA activity e.g. disease activity scores (DAS-28) demonstrating worse rheumatoid 
arthritis and higher levels of RA seropositivity [7]  
We therefore wished to explore if BROS was associated with poorer outcomes 
compared to BR without RA. Defining the clinical severity of bronchiectasis has been 
problematic until recent scoring indices such as the Bronchiectasis Severity Index (BSI) 
became available[8].  We therefore aimed to assess mortality, frequency of exacerbations, 
hospital admissions, reported health related quality of life and BSI scores in an international 
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cohort comparing BROS to BR without RA. Idiopathic bronchiectasis was used as a 
benchmark due to its prevalence and a perception that this aetiological group may have better 
outcomes.[1] As bronchiectasis and COPD overlap syndrome (BCOS) has been linked to 
excess mortality we used this second group as an additional reference group[9]. 
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Methods 
 
Multicentre assessment of bronchiectasis severity  
 
Six independent cohorts of patients were collected from specialist Bronchiectasis services in 
Edinburgh, Dundee and Newcastle (UK), Leuven (Belgium), Monza (Italy) and Galway 
(Ireland) with an average follow up of 4 years[8,10].  Consecutive adult patients were 
enrolled on the basis of a diagnosis of bronchiectasis made by high resolution computed 
tomography (HRCT) and a clinical history consistent with bronchiectasis.[1] Patients were 
excluded if they had active malignancy at enrolment, cystic fibrosis, active mycobacterial 
disease (including active non-tuberculous mycobacteria (NTM)), HIV or a primary diagnosis 
of pulmonary fibrosis/sarcoidosis with secondary traction bronchiectasis. Patients with BCOS 
were not included within the Edinburgh cohort due to their cohort building protocol. Cohort 
building was approved at each individual centre; by the South East Scotland Research Ethics 
Committee, Research ethics service multi-centre ethics - IRAS 12324 and by NRES, UK 
12/NE/0298, CA 128 Clinical research committee, Galway [8,10].  
 
Aetiological categorisation 
The underlying aetiology of bronchiectasis was determined following testing recommended 
by the British Thoracic Society (BTS) guidelines [1]. This includes serological and clinical 
assessment for Rheumatoid arthritis [1]. 
BROS required a diagnosis of both BR, as above, and Rheumatoid arthritis, defined 
according to the 2010 American College of Rheumatology (ACR) and European League 
Against Rheumatism (EULAR) RA criteria [11] and local prevailing clinical guidelines. 
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Patients were grouped into the BROS category irrespective of which of the two conditions 
preceded the other.  
Patients were pragmatically categorised as BCOS based on evidence of airflow obstruction 
and smoking greater than 20 pack years. The presence of emphysema on CT scan was not a 
pre-requisite. 
Post-infectious causes were attributed when a clear history of bronchiectasis after an acute 
infectious episode was reported[1]. Inflammatory bowel disease and ABPA associated 
aetiological categories were applied when a clear history and/or appropriate serological and 
history were reported respectively. Idiopathic was attributed as a diagnostic grouping in the 
absence of any recognised aetiology.  “Other bronchiectasis” was a grouping of categories 
that included all remaining aetiological groups (e.g. immunodeficiency associated 
bronchiectasis- including those on immunoglobulin replacement, ciliary dyskinesia etc). 
Clinical assessments 
At the time of clinical assessment all patients were clinically stable with no antibiotic use in 
the preceding 4 weeks. All patients underwent spirometry (forced expiratory volume in one 
second (FEV1) and forced vital capacity (FVC) according to ERS guidelines with the highest 
of three technically satisfactory measurements recorded).  
Radiological severity 
Radiological severity of bronchiectasis was assessed using a modified Reiff score which has 
been used previously bronchiectasis studies.[8,12,13] The score assesses the number of lobes 
involved (with the lingula considered to be a separate lobe) and the degree of bronchial 
dilatation (tubular-1, varicose-2 and cystic-3) with a maximum score of 18 and minimum 
score of 1. There was no minimum Reiff score for patients to be entered into the cohorts. 
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Bacteriology 
As previously described all bacteriology was performed using local culture protocols on 
spontaneous early morning sputum samples.[3] The definition of chronic persistent infection, 
was the isolation of potentially pathogenic bacteria in sputum culture on 2 or more occasions, 
with at least 3 months apart in a one year period.[13,14,15] The micro-organism grown most 
frequently over the study period was classed as the predominant pathogen. The clinical 
standards were sputum sampling at 6 monthly or more frequent intervals at clinic reviews.  
BSI scores 
As previously described, BSI scores were grouped as follows; scores 0-4 represents mild 
bronchiectasis, scores 5-8 moderate bronchiectasis and scores >8 represents severe 
bronchiectasis.[8] 
End-points 
Mortality: At the end of the follow-up periods, mortality was determined through notes 
review and interrogating national death records. Survival status was confirmed for 100% of 
participants although exact date of death was not available for all deceased patients. 
Exacerbations were defined according to the BTS definition as an acute deterioration with 
worsening and/or systemic upset[1]. Severe exacerbations were defined as those needing 
hospitalisation. The frequency of exacerbations requiring antibiotic treatment were 
determined from clinic records and patient histories and verified against primary care 
prescription records. 
  
Statistical analysis  
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Normally distributed data are presented as mean with standard deviation, whilst non-normally 
distributed data are presented as median with interquartile range. The Chi square test and 
Mann Whitney U test were used for comparison of categorical and numerical data 
respectively. For comparisons of more than 2 groups, one way ANOVA or the Kruskal-
Wallis test were used as appropriate. For all analyses a value of p<0.05 was considered 
statistically significant. Independent relationships between BROS and BCOS with mortality 
were assessed using multivariable logistic regression, adjusting for the BSI. Data are 
presented as odds ratios (OR) with 95% confidence intervals (CI). Kaplan Meier survival 
curves and Cox-proportional hazards regression were performed for survival. The 
discrimination of the BSI for predicting mortality in BROS was assessed using the area under 
the receiver operator characteristic curve (AUC). We performed sensitivity analyses to 
determine if outcomes were different across all 3 BSI categories (mild, moderate and severe). 
Additionally we applied calibration analysis - an analysis to determine whether scoring 
systems perform similarly in a different population compared to the baseline population. As a 
sensitivity analysis to determine the validity of pooling cohorts, the authors used random 
effects meta-analysis. Data were pooled using the Mantel-Haenszel method and heterogeneity 
assessed using Higgins I2 test and Cochrans Q test. 
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Results  
 
Multi-centre assessment 
We collected data from 1716 adult patients with bronchiectasis across 6 centres in Western 
Europe. The data is displayed in Table 1 and Figure 1. The median age was 65 years with a 
female predominance and the commonest aetiological groups were idiopathic and post-
infectious suggesting these were broadly representative of bronchiectasis cohorts previously 
reported.[1]  
Overall BROS was present in 8.5% of the cohort whilst BCOS was present in 12% of the 
cohorts that included BCOS during cohort building. The mean exacerbation frequency was 
greater than 2 exacerbations per year and all cohorts reported a prior history of hospitalisation 
in at least 20% of patients. Chronic Pseudomonas aeruginosa infection was present in a mean 
of 13% of patients overall. The mean BSI scores for each centre ranged from 6-9. Prior data 
has demonstrated this is consistent with patients with moderate to severe bronchiectasis [8]. 
The centre with the highest hospital admission rate (Newcastle) also had the highest observed 
mean BSI score 9.6. 
 
 
Comparison between BROS and non-RA patients with bronchiectasis 
The comparisons between BROS and other groups are shown in table 2. In general the BROS 
patients were similar in terms of age and gender distribution except when compared to the 
BCOS group who were significantly older and significantly more likely to be male. The BSI 
scores were statistically significantly higher in the BROS group as compared to idiopathic 
and other BR though all remained within the moderate severity category of the BSI (scores  
5-8). Radiological burden of disease was not significantly different across all groupings with 
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3 lobes involved as an average. Notably both BCOS and BROS groups had statistically 
significantly more exacerbations and prior bronchiectasis-related hospitalisations than the 
idiopathic bronchiectasis group (mean/ median 2.4 and 2.7 vs 1.8 p <0.05 and 26.1 and 
58.4% vs 25.1% p<0.05). As expected the mean FEV1% predicted was both statistically and 
clinically significantly lower in the BCOS group, in part reflecting the need for airflow 
obstruction to be present in this diagnostic grouping. 
 
 
Outcomes in BROS 
The mortality rate over a mean of 48 months follow up was 8.6% in patients with “other” 
causes of BR, 9.3% idiopathic BR, 18% for RA and 28.5% for COPD. There was no 
significant difference in follow-up duration between any of the four cohorts to explain the 
differences in mortality (mean 46, 48, 47 and 47 months respectively)- Figure 2. 
Using logistic regression, there was a significant univariate association between RA and 
increased mortality (Odds Ratio (OR) 1.82, 95% Confidence Interval (CI) 1.15-2.89, p=0.01). 
This persisted after multivariable adjustment for BSI; OR 1.83, 95% CI 1.11-3.02, p=0.01.  
The relationship was greater in the fully adjusted model (including aetiology, all BSI 
individual components) - OR 2.03 95 CI 1.19-3.44, p=0.009. 
COPD was also independently associated with worse outcome in all models adjusted OR 
2.47, 95% CI 1.55-3.92 (in the fully adjusted model). No other aetiologies were 
independently associated with outcome (Hosner-Lemeshow goodness of fit test p=0.7 
indicating excellent model fit).  
There was, however, no significant relationship between RA and hospital admission risk 
during follow-up (OR 0.84, 95% CI 0.42-1.67, p=0.6). There was no significant relationship 
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between RA and more frequent exacerbations using multiple linear regression (adjusted for 
BSI, estimate 0.15 std err 0.18, p=0.5).  
The results were confirmed using Cox-proportional hazard regression. The Hazard ratio for 
RA and mortality was 1.88, 95% CI 1.11-3.21, p=0.01. The Kaplan Meier survival curve is 
shown both for BCOS, BROS (figure 2) 
 
Prediction 
Despite clear variations in mortality rates associated with different aetiologies, the BSI 
showed good discrimination in patients with BROS giving an AUC of 0.77, 95% CI 0.67-
0.87, p<0.0001).  
Additionally we applied calibration analysis to determine whether the BSI scoring systems 
perform similarly well in a different population, such as BROS when compared to the overall 
BR population. Rheumatoid Arthritis was associated with an increased mortality risk across 
all BSI subgroups – OR 2.57, 95% CI 0.48-13.9 in low risk patients, 2.1 (0.8-5.5) in 
intermediate risk and 1.64 (0.83-3.3) in high risk patients. Interaction test p=0.8. This 
analysis indicated that RA increases the risk across the full spectrum of bronchiectasis 
severity categories and should be considered additive to the BSI. 
 
Validation of the pooled analysis 
Using random effects meta-analysis of the 6 cohorts, RA was associated with increased 
mortality (OR 1.70, 95% CI 1.07-2.70, p=0.02). Importantly there was no heterogeneity in 
this relationship across all 6 studies. I2=0%, Cochrans Q test p=0.6.  
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Discussion 
Bronchiectasis  (BR) and rheumatoid arthritis (RA) are undoubtedly linked and may present 
in patients in a variety of temporal and causal ways [4,5,7]. Bronchiectasis appears to 
predispose to later Rheumatoid arthritis and BRRA could be used to define this syndrome [5]. 
Patients with RA are known to develop bronchiectasis as their articular disease progresses 
and could be described as RABR. A third group could include those who coincidentally have 
both conditions without any causal relationship. Reflecting concerns over recall bias and 
inaccuracy in pinpointing the onset of a particular condition (in contrast to the time when it 
was diagnosed) we have opted to use the terminology BROS to encompass all three of these 
scenarios. This study is the first multi-centre international study to apply the recently 
validated BSI to define the severity of bronchiectasis in patients with comorbid RA.  We 
report data in almost 150 patients with BROS from a 1716 patient cohort followed over an 
average of 4 years with bronchiectasis in the largest and only multi-centre study to date to 
define the impact of RA in BR. We benchmarked this group against a group increasingly 
recognised to have poorer outcome namely those with Bronchiectasis–COPD overlap 
syndrome (BCOS) and those often perceived to have more favourable outcomes namely 
“idiopathic bronchiectasis”. We found however that whilst there was a statistically 
significantly higher BSI score in the BROS group when compared to idiopathic 
bronchiectasis (BSI mean 7.7 vs. 7.1, p <0.05), this was not likely to be clinically significant 
as the mean BSI scores were both within the moderate BSI category (BSI score 5-8).     
Importantly however, we show that BROS is significantly associated with increased 
mortality as compared to idiopathic bronchiectasis syndrome. Indeed the mortality in the 
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BROS overlap syndrome reached towards that seen in BCOS [9,16]. Using multiple 
modelling methods we show that the mortality risk over 4 years is increased by 
approximately 80% and when adjusted for all components of the BSI that the odds ratio 
reached 2.0 indicating a doubling of mortality risk. This effect was replicated in survival 
analyses confirming that BROS is associated with higher mortality. Importantly this appears 
independent of the rates of hospitalisation, non-hospitalised exacerbations, spirometric and 
radiological markers of disease burden. 
The co-existence of BR  and RA has previously been suggested to have major clinical 
significance: In 1997, a single centre UK study reported that patients with both BR and RA 
(BROS) had greatly elevated standardised mortality ratios 7.3 times higher than the general 
population, 5 times that of patients with RA alone and 2.4 times that of patients with BR over 
5 years [17] Our observed mortality rates herein were 18% and the Odds Ratio for mortality 
was slightly less than that reported in the above study. Careful review of this prior work 
suggests potential case ascertainment bias with a more severe BROS subgroup selected- only 
32 patients with BROS were identified from their RA cohort of 3000 (1%). Their reported 
prevalence rate is lower than we observed (~8%) and contrasts to more recent studies 
suggesting prevalence rates ranging from 3% to 30% radiologically. Nevertheless a recent 
single centre case-control study of patients recruited 1999-2002 reported an excess of 
mortality over an 11 year period of follow up[18].  The patients with BROS had also a poorer 
prognosis in terms of survival after RA diagnosis (HR, 8.6; 95% CI, 1.5-48.2; P = 0.014) and 
from birth (HR, 9.6; 95% CI, 1.1-81.7; P = 0.039). Divergence in mortality rates was seen 
within the first 5 years in this study. Collectively these prior data and our international multi-
centre observations support BROS as a risk for poorer outcomes.  
The reasons for this may be distinct to the pulmonary disease component as suggested 
by the similar rates of exacerbation and lung function seen between BROS and idiopathic BR  
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noted herein. This effect may be more clearly seen in those with milder bronchiectasis as 
suggested by our sensitivity analysis. It is possible that the treatments used for rheumatoid 
arthritis, which include powerful immunosuppressant drugs, may impact on survival but our 
study was not designed to define the reasons for poorer outcomes. In this study we did not 
have funding to collect detailed information on the management of RA and therefore are 
unable to assess the role this has in the observed increased mortality. Notably however in our 
prior work we have not seen significantly different rates of disease modifying anti-rheumatic 
drugs (DMARD) therapy between RA and BROS patients in an intensively characterised UK 
cohort [19]. We could however demonstrate greater rates of autoantibody seropositivity, 
inflammatory markers and joint involvement suggesting the BROS syndrome is associated 
with greater immune activation and systemic inflammation [19,20]. This is noteworthy as RA 
has been associated with an excess of cardiovascular deaths and is now incorporated as 
independent risk factor in the cardiovascular Q-RISK2 scoring system [21]. Bronchiectasis 
has also been recently linked with excessive cardiovascular risk [22] and this may be an 
underpinning mechanism for excess mortality in BROS with additive cardiovascular risk 
driven by each pro-inflammatory comorbidity. This requires further mechanistic research that 
was not possible herein as only limited data collection was possible.   
We have also shown that the BSI scoring system still predicts poorer mortality 
outcomes in those with BROS and that the effects are seen across the range of BSI categories. 
RA is certainly an additive and independent predictor of severity/death and aetiology may 
need incorporated into future risk stratification systems.  
To benchmark the outcomes in BROS we used a previously described bronchiectasis 
aetiology associated with poor outcomes.  
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We show that BCOS has an elevated mortality risk  (28% risk of death over 4 years), 
which is much higher than that reported in the selected population recruited into the TORCH 
study of COPD (patients who had an average FEV1 of ~60% (15% mortality over 3 
years).[23] The mortality rates in the BCOS population were high and in the order of those 
reported in GOLD stage II/III COPD patients (or those within BODE index quartile 3) in the 
BODE index cohort and in more recent studies.[24, 25]  We extend the findings of Gatheral 
et al demonstrating that BCOS is associated with a high hospital admission rate (58% in this 
series) and that  persistent Pseudomonas aeruginosa infection is common in BCOS (24% 
herein).[25] In contrast to this recent paper from the UK which did not show an excess of 
mortality in BCOS when compared to COPD alone [26] we confirm work from others 
[9,16,27] that BCOS is associated with excess mortality when compared to other 
bronchiectasis aetiologies. These differences may be explained by the comparator groups; 
Gatheral compared BCOS to relatively severe COPD patients whilst in the other studies and 
our current study, the comparator group has been bronchiectasis often including those with 
mild disease [26,27]. Our definition of BCOS may have incorrectly categorised idiopathic 
bronchiectasis patients who previously smoked as BCOS. Nevertheless our pragmatic 
definition appears to have confirmed the findings reported from single centres [9,16,27]. 
There is a consensus on the need to better define bronchiectasis phenotypes and predictors of 
mortality [28,29]. One area to focus upon is BCOS, a syndrome that is clearly adversely 
prognostic yet difficult to define precisely and mechanisms leading to adverse outcomes are 
unclear [reviewed in 29]. BROS clearly is another area also requiring better understanding. 
We do not have prescription records of immunosuppressive therapies to target rheumatoid 
arthritis this patient population- such therapies may influence both infection rates and 
possibly mortality in the setting of BROS. These data will be prospectively collected in UK 
national and European observational cohorts and should allow future associations to be 
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explored (www.bronch.ac.uk)[30]. Our study has inherent limitations in addition to those 
relating to concomitant medications: We excluded patients with active non-tuberculous 
mycobacterial disease and patients with known RA-related interstitial lung disease.  These 
factors may have contributed to the differences in the BSI scores between groups. We cannot 
however exclude the possibility of “missed” cases of BROS being incorrectly classified as 
idiopathic BR in any of the cohorts though serological testing for rheumatoid arthritis was 
conducted in all cohorts. The pooling of data from multiple centres may be regarded as a 
limitation, as there was some heterogeneity in the populations, such as the exclusion of 
BCOS patients from the Edinburgh cohort (that reflected an a priori  decision at that 
recruiting centre [8]. Nevertheless in our sensitivity analysis we demonstrate no significant 
heterogeneity in the relationship between BROS and mortality and therefore we regard the 
robustness of this finding across multiple centres as a strength and not as a weakness. We did 
not assess RA serology repeatedly only doing so when at a patients’ first clinic review or 
when new symptoms prompted a clinical suspicion of RA. Therefore it is possible that our 
BR patients may have inadvertently included some subclinical or early stage RA that should 
have been placed in the BROS category. Lastly, our mortality data did not compare outcomes 
in BROS with a cohort of patients with RA alone nor included the recorded cause of death; 
these data will be highly relevant to future studies.  
In conclusion, in the largest cohort studied to date, both BROS and BCOS have both 
been shown to be associated with poorer outcomes and should be investigated further as a 
priority in longitudinal and mechanistic studies to assess drivers of mortality [28,29]. The 
current data support the premise that BROS patients are at higher risk of premature death and 
a multidisciplinary approach involving chest and rheumatology physicians is needed. Patients 
with BROS with “mild” bronchiectasis defined radiologically by extent or by using 
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composite scoring systems may need closer monitoring than those with other aetiologies 
causing bronchiectasis. 
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Table 1 Details of the European Bronchiectasis  Cohorts 
 
Leuven 
(Belgium) 
Galway 
(Ireland) 
Monza 
(Italy) 
Edinburgh 
(UK) 
Newcastle 
(UK) 
Dundee 
(UK) 
Total, n. 
(%) 
253  
(100) 
242  
(100) 
201  
(100) 
608  
(100) 
126 
 (100) 
286  
(100) 
Demographic         
Age (median, 
 IQR)) 
68  
(56-78) 
63  
(53-71) 
68  
(59-73) 
67  
(58-75) 
61  
(54-69) 
68  
(61-75) 
Male Gender 127 (50%) 76 (31%) 80 (39%) 243(40%) 51 (41%) 115(42%) 
Aetiology*       
Idiopathic 78 (31%) 98 (40%) 79 (39%) 261 (42%) 52 (41%) 124 (43%) 
Post-infective 50 (19%) 41 (17%) 51 (25%) 207 (34%) 28 (22%) 51 (17%) 
ABPA 15 (6%) 5 (2%) 4 (2%) 49 (8%) 8 (6%) 31 (11%) 
BCOS 42 (17%) 26 (11%) 49 (24%) 0 (excl) 15 (12%) 7 (2%) 
Immuno- 
deficiency 
18 (7%) 13 (5%) 9 (4%) 6 (1) 14 (11%) 16 (6%) 
BROS 25 (10%) 55 (23) 2 (1%) 44 (7%) 11 (9%) 10 (4%) 
IBD 5 (2%) 4 (2%) 6 (3%) 14 (2%) 2 (1%) 8 (3) 
Severity markers       
Exacerbations/yr 
 
1.8 (2.0) 3.2 (1.3) 1.9 (1.9) 1.7 (2.0) 3.4 (1.7) 2.1 (1.8) 
Prior hospital 67 (26%) 63 (26%) 56 (27%) 133 (21%) 74 (58%) 66 (23%) 
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admissions – n (%) 
%P. aeruginosa 20 (8%) 35 (14%) 39 (19%) 70 (12%) 13 (10%) 37 (14%) 
Lobes involved on 
CT 
(mean/ SD) 
2.9 (1.3) 2.7 (1.3) 2.8 (1.4) 3.0 (1.6) 2.8 (1.4) 3.2 (1.6)  
Mean FEV1 % pred 70.1 (27) 77.5 (24) 71.7 (35) 72.6 (25) 64.0 (27) 72.1 (26) 
Mean BSI score 
 
6.7 (4.8) 7.2 (4.4) 7.2 (4.5) 7.3 (4.8) 9.6 (4.9) 7.1 (4.5) 
 
Key; ABPA allergic bronchopulmonary aspergillosis, BCOS Bronchiectasis-COPD overlap 
syndrome, BROS bronchiectasis- Rheumatoid arthritis, IBD inflammatory bowel disease, 
BSI Bronchiectasis severity index, CT – computerised tomography scan. FEV1 Forced 
expiratory volume 1 second. Less frequent aetiologies not shown. Data are presented as mean 
(standard deviation) or N(%) unless otherwise stated. Excl- BCOS patients were excluded 
from this cohort. 
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Table 2 Comparison between BROS and non-RA patients with bronchiectasis 
 
 
 BROS Idiopathic BR BCOS Other BR 
Age (median-
IQR) 
69 (60-
76)# 
67 (58-74)# 73 (65-78)* 64 (55-72)*# 
Gender 34.3% 
male# 
38.2% male# 70.0% male* 38.4% male# 
Exacerbations/yr 2.4 (1.9) 1.8 (1.9)*# 2.7 (2.0) 2.2 (2.0) 
Prior hospital 
admissions 
26.1%# 
 
25.1%# 
 
58.4%* 
 
23.7%# 
% P. aeruginosa 14.3%# 14.7%# 24.1%* 14%# 
Lobes involved 
on CT 
3.0 (1.5) 2.8 (1.5) 3.1 (1.4) 3.0 (1.5) 
Mean FEV1 % 
pred 
76% (25)# 76% (25)# 51% (22)* 74% (25)# 
Mean BSI score 7.7 (4.6)# 7.1 (4.6)*# 10.4 (4.5)* 6.9 (4.3)*# 
 
Key; BROS bronchiectasis- rheumatoid arthritis,  BCOS Bronchiectasis-COPD overlap 
syndrome, BSI Bronchiectasis severity index, CT – computerised tomography scan. FEV1 
Forced expiratory volume 1 second *= p<0.05 compared with BROS, #= p<0.05 compared 
with BCOS. Data are presented as mean (standard deviation) or N(%) unless otherwise 
stated. 
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CONSORT 2010 Flow Diagram 
 
Assessed for eligibility (n=1956)  
) 
Excluded (n= 165) 
♦   Not meeting inclusion criteria (n= 89 ) 
♦   Declined to participate (n=76  ) 
 
Analysed (n= 1724)  
♦ Excluded from analysis (incomplete data) 
(n= 8) 
Lost to follow-up (left centre) (n= 67 ) 
Analysis 
Follow-Up 
Enrolled (n= 1791) 
Enrollment 
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